Document:

Exhibit 10.6
​
CERTAIN INFORMATION IDENTIFIED WITH [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

​
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1.  CONTRACT ID CODE
	PAGE OF PAGES

	​
	S
	1
	3

	2.  AMENDMENT/MODIFICATION NO.
P00001
	3.  EFFECTIVE DATE
16-Sep-2020
	4.  REQUISITION/PURCHASE REG. NO.
SEE SCHEDULE
	5.  PROJECT NO. (If applicable)

	6. ISSUED BY 
	CODE
	W911QY
	7.  ADMINISTERED BY (If other than item 6)CODE
	S2101A

	W6QK ACC-APG NATICK DIVISION
[***]
	DEFENSE CONTRACT MANAGEMENT AGENCY
DCMA BALTIMORE
217 EAST REDWOOD STREETSCD:  A
SUITE 1800
BALTIMORE MD 21202-3375

	8.  NAME AND ADDRESS OF CONTRACTOR (No., Street, Country, State and Zip Code)
NOVAVAX, INC.
20 FIRSTFIELD RD
GAITHERSBURG MD 20878-1760
	​
	9A.  AMENDMENT OF SOLICITION NO.

	​
	​
	9B.  DATED (SEE ITEM 11)

	​
	X
	10A.  MOD. OF CONTRACT/ORDER NO.
W911QY20C0077

	​
	​
	X
	10B.  DATED (SEE ITEM 13)
04-Jun-2020

	CODE1UCZ4
	FACILITY CODE
	​
	​

	11.  THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	​
☐
	​
The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer ☐  is extended, ☐ is not extended.
Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods: (a) By completing Items 8 and 15, and returning                copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATE DATA (if required)
See Schedule

	13.  THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT/ORDERS
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	​
	A.

THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	​
	B.

THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).

	​
	C

THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

	X
	D.OTHER (Specify type of modification and authority)
FAR Clause 52.232-22 Limitation of Funds

	E. IMPORTANT:  Contractor ☒ is not, ☐ is required to sign this document and return               copies to the issuing office.

	14.  DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible)
Modification Control Number:soconnel202894
The purpose of this modification is to add incremental funding as follows:
​
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore change, remains unchanged and in full force and effect.

	15A.  NAME AND TITLE OF SIGNER (Type or print)
	16A.  NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
[***] / CONTRACTING OFFICER
TEL: [***]EMAIL: [***]

	15B.  CONTRACTOR/OFFEROR
                                                                  
(Signature of person authorized to sign)
	15C.  DATE SIGNED
	16B.  UNITED STATES OF AMERICA
BY​ ​     /s/ [***]                                           
(Signature of Contracting Officer)
	16C.  DATE SIGNED
16-Sep-2020

​
​
​

​
	Exception TO SF 30
	30-105-04
	STANDARD FORM 30 (Rev. 10-83)
Prescribed by GSA
FAR (48 CFR) 53.243

​

​

SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
SECTION B - SUPPLIES OR SERVICES AND PRICES
SUBCLIN 000103 is added as follows:
​
	​

	​

	​

	​

	​

	​

	ITEM NO
	SUPPLIES/SERVICES
	QUANTITY
	UNIT
	UNIT PRICE
	AMOUNT

	000103
	Funding for CLIN 0001
	​
	​
	​
	$0.00

	​
	COST
	​
	​
	​
	​

	​
	PURCHASE REQUEST NUMBER: 
	0011504522-0001
	​
	​
	​

	​
	​
	​
	ESTIMATED COST
	​
	$0.00

	​
	ACRN AC
	​
	​
	​
	$8,000,000.00

	​
	CIN: GFEBS001150452200003
	​
	​
	​
	​

	​
	​
	​
	​
	​
	​

​
SECTION E - INSPECTION AND ACCEPTANCE
The following Acceptance/Inspection Schedule was added for SUBCLIN 000103:
​
	INSPECT AT
	INSPECT BY
	ACCEPT AT
	ACCEPT BY

	N/A
	N/A
	N/A
	N/A

​
SECTION G - CONTRACT ADMINISTRATION DATA
Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $8,000,000.00 from $21,952,384.00 to $29,952,384.00.
SUBCLIN 000103:
Funding on SUBCLIN 000103 is initiated as follows:
ACRN: AC
​
CIN: GFEBS001150452200003
​
	​

	​

	​

	Acctng Data: 09720202021013000018170552520252
	S.0074658.1.1.5
	6100.9000021001

​
Increase: 
​
$8,000,000.00]Total:
​
$8,000,000.00
​
Cost Code: AHPDD
 (End of Summary of Changes)

Page 2 of 3AMENDMENT No. 1 TO AMENDED AND RESTATED RESEARCH, COLLABORATION AND LICENSE AGREEMENT
​
This AMENDMENT No. 1 to the Amended and Restated Research, Collaboration and License Agreement dated May 5, 2020 (“Amendment No. 1 to Restated Agreement”) is entered into as of August 13, 2020 (the “Amendment No. 1 to Restated Agreement Effective Date”) by and between Passage Bio, Inc., a corporation organized under the laws of Delaware (“Passage”) with offices at 2001 Market St, 28th Floor, Philadelphia, PA 19103, and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3600 Civic Center Blvd., 9th Floor, Philadelphia, PA 19104 (“Penn”) and amends the Amended and Restated Research Collaboration and License Agreement dated May 5, 2020 (the “Restated Agreement”). Passage and Penn are referred to collectively as the “Parties” and individually as a “Party.”
​
WHEREAS, the Parties wish to amend the Restated Agreement; and
​
NOW, THEREFORE, in consideration of the promises and mutual covenants contained in the Restated Agreement and herein, and intending to be legally bound hereby, the Parties amend the Restated Agreement and otherwise agree as follows:
​
		1.	The Research Program contained in Exhibit B of the Restated Agreement is hereby amended to include the additional work outlined in Schedule A to this Amendment No.1 to Restated Agreement.	

​
		2.	The budget for the additional work is included in Schedule B to this Amendment No. 1 to Restated Agreement, and this budget is intended to be in addition to those previously included under the Restated Agreement. Schedule B also includes the inventory of plasmids purchased on behalf of Passage and available to Passage as of May 16, 2020.	

​
		3.	A complete amended and restated payment schedule is set forth as Schedule C to this Amendment No. 1 to Restated Agreement . The payment schedule denotes payments for the Research Program that have already been made to Penn as well as future payments owed to Penn, as of June 30, 2020.	

​
		4.	This Amendment No. 1 to Restated Agreement and the Restated Agreement contain the entire understanding between the Parties and supersede any and all prior agreements, understandings and arrangements whether written or oral between the Parties with respect to the matters contained in the Restated Agreement and this Amendment No. 1 to Restated Agreement. No amendments, changes, modifications or alterations of the terms and conditions of this Amendment No. 1 to Restated Agreement shall be binding upon any Party, unless provided in writing and signed by an authorized representative of each Party.	

​
		5.	All terms and conditions of the Restated Agreement not changed by this Amendment No. 1 to Restated Agreement shall remain in full force and effect.	

​
		6.	Signatures on this Amendment No. 1 to Restated Agreement may be communicated by e-mail transmission and shall be binding upon the Parties upon receipt by transmitting the same by e-mail, which signatures shall be deemed originals. If executed in counterparts, the Amendment No. 1 to Restated Agreement shall be effective as if simultaneously executed.	

​
(Signature page follows.)
​
​

IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Agreement as of the Restatement Date.
​
	Ill Quigley

	​

	​

	​

	​

	AGREED ON BEHALF OF:
​
THE TRUSTEES OF THE UNIVERSITY OF
PENNSYLVANIA
	    
	AGREED ON BEHALF OF:
​
PASSAGE BIO, INC.

	​
	​
	​

	By:
	/s/ John S. Swartley
	​
	By:
	/s/ Jill Quigley

	Name:
	John S. Swartley, PhD
	​
	Name:
	Jill Quigley.

	Title:
	Associate Vice Provost for Research and Executive Director, Penn Center for Innovation
	​
	Title: 
	Chief Operating Officer

​
ACKNOWLEDGED AS READ AND UNDERSTOOD BY INSTITUTION PRINCIPAL INVESTIGATOR
​

/s/ James Wilson
(Signature)
​
Name: Dr. James Wilson

​swav-ex101_30.htm

Exhibit 10.1

SHOCKWAVE MEDICAL, INC.
AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION PLAN

This Shockwave Medical, Inc. Amended and Restated Non-Employee Director Compensation Plan (this “Plan”) was adopted by the Board of Directors (the “Board”) of Shockwave Medical, Inc. (the “Company”) on February 20, 2019, and became effective on February 20, 2019. As amended and restated below, this Plan was adopted by the Compensation Committee of the Board on September 30, 2020 and became effective on such date.

1.Eligibility. Each member of the Board who is not a full- or part- time officer or employee of the Company (a “Non-Employee Director”) is eligible to participate in this Plan during the period of the Non-Employee Director’s service as a member of the Board.

2.Annual Cash Fees.

a.Annual Board Member Fee. Each Non-Employee Director will earn cash compensation for service as member of the Board at an annual rate of $40,000 (such compensation, the “Annual Board Member Fee”).

b.Annual Non-Executive Chair Fee. Any Non-Employee Director serving as “Non-Executive Chair” of the Board will earn additional cash compensation for such service at an annual rate of $45,000 (such additional compensation, the “Annual Non-Executive Chair Fee”).

c.Annual Committee Chair Fees. Each Non-Employee Director serving as the chair of one or more of the following committees of the Board will earn cash compensation for such service at the annual rate set forth here (such compensation, the “Annual Committee Chair Fee”):

	
 
	
i.
	
$20,000 for the chair of the Audit Committee;

	
 
	
ii.
	
$15,000 for the chair of the Compensation Committee; and

	
 
	
iii.
	
$10,000 for the chair of the Nominating and Corporate Governance Committee.

d.Annual Committee Member Fee. Each Non-Employee Director serving as a non-chair member of one or more of the following committees of the Board will earn cash compensation for such service at the annual rate set forth here (such compensation, the “Annual Committee Member Fee”):

	
 
	
i.
	
$10,000 for each member of the Audit Committee;

	
 
	
ii.
	
$7,500 for each member of the Compensation Committee; and

	
 
	
iii.
	
$5,000 for each member of the Nominating and Corporate Governance Committee.

e.Payment. The Annual Board Member Fee, Annual Non-Executive Chair Fee, Annual Committee Chair Fee and Annual Committee Member Fee (together, the “Annual Fees”) earned by each Non-Employee Director will be paid quarterly in arrears on the last business day of each calendar quarter. In the event that a Non-Employee Director serves on the Board, as Non-Executive Chair or as a chair or member of a committee for less than an entire quarter, the portion of the applicable Annual Fees earned and 

 

payable for such quarter will be prorated based on the number of days in such quarter for which such Non-Employee Director provided such service.

3.Initial Equity-Based Compensation for New Non-Employee Directors.  Upon the election of a Non-Employee Director to the Board who has not previously served on the Board, such director shall receive an award (an “Initial Award”) of restricted stock units (“RSUs”) under the Shockwave Medical Inc., 2019 Equity Incentive Plan (the “Equity Plan”), with a value equal to $180,000, based on the grant date closing price of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The grant date of the Initial Award shall be the date of such director’s election to the Board, or the earliest practicable date thereafter, as determined by the Company’s Chief Executive Officer or Chief Financial Officer. The Initial Award shall vest in equal annual installments over three years from the date of grant, subject to the applicable director’s continued service on the Board through the applicable vesting date. The Initial Award shall be granted pursuant to the Company’s standard form RSU award agreement, and subject to the terms and conditions therein.

4.Annual Equity-Based Compensation for Non-Employee Directors.  An annual grant of RSUs (an “Annual Award”) shall be made under the Equity Plan to each Non-Employee Director following each annual meeting of stockholders of the Company. The Annual Award shall have a value equal to $120,000, based on the grant date closing price of the Common Stock. The grant date of the Annual Award shall be the date of such annual meeting of stockholders of the Company, or as the earliest practicable date thereafter, as determined by the Company’s Chief Executive officer or Chief Financial Officer. The Annual Award shall vest in full on the earlier of (i) one year following the date of grant or (ii) the following year’s annual meeting of stockholders, subject to the applicable director’s continued service on the Board through the vesting date. The Annual Award shall be granted pursuant to the Company’s standard form RSU award agreement, and subject to the terms and conditions therein.

5.Cash Equivalent for Equity Award.  In each case where an Non-Employee Director is an equity partner or service provider of a private equity sponsor of the Company, and such sponsor has informed the Company in writing that it does not allow its equity partners or service providers, as the case may be, to accept awards of equity for compensation for services rendered to boards of directors of its portfolio companies, then such Non-Employee Director shall be eligible to receive a cash award in lieu of any Initial Award or Annual Award (each, a “Cash Equivalent Award”) with a value equal to the designated value of the equity award that would otherwise be provided hereunder, but otherwise subject to the same terms and conditions applicable to such award.

6.Administration. This Plan will be administered by the Board, or if the Board so determines in its discretion, by the Compensation Committee of the Board (the “Committee”). The Board (or the Committee, as the case may be) will have the power to construe this Plan, to determine all questions hereunder, and to adopt and amend such rules and regulations for the administration of this Plan as it may deem desirable. All decisions, determinations and interpretations of the Board (or the Committee, as the case may be) with respect to this Plan will be final and binding.

7.Transfer and Assignment. The right of a Non-Employee Director to receive the payment of all or a portion of an Annual Fee or to be granted an Initial Award or Annual Award may not be assigned, transferred, pledged or encumbered, other than by will or the laws of descent and distribution and any attempted assignment or transfer will be null and void.

8.Governing Law. This Plan will be administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof.

 

9.Amendment and Termination. The Board (or the Committee, if so authorized by the Board) may amend, modify or terminate this Plan for any reason at any time; provided, that no amendment, modification or termination, without the consent of the applicable Non-Employee Director, will materially adversely affect any then issued and outstanding Initial Award or Annual Award held by such Non-Employee Director.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]